Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
Company profile
Ticker
KIN
Exchange
Website
CEO
Richard Chin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
KindredBio Equine, Inc. • Centaur Biopharmaceutical Services, Inc. ...
IRS number
461160142
KIN stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
7 Sep 21
EFFECT
Notice of effectiveness
2 Sep 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
POS AM
Prospectus update (post-effective amendment)
30 Aug 21
8-K
Termination of a Material Definitive Agreement
30 Aug 21
25-NSE
Exchange delisting
27 Aug 21
Transcripts
KIN
Earnings call transcript
2021 Q1
12 May 21
KIN
Earnings call transcript
2020 Q4
17 Mar 21
KIN
Earnings call transcript
2020 Q3
9 Nov 20
KIN
Earnings call transcript
2020 Q2
8 Aug 20
KIN
Earnings call transcript
2020 Q1
10 May 20
KIN
Earnings call transcript
2019 Q4
16 Mar 20
KIN
Earnings call transcript
2019 Q3
12 Nov 19
KIN
Earnings call transcript
2019 Q2
2 Aug 19
KIN
Earnings call transcript
2019 Q1
10 May 19
KIN
Earnings call transcript
2018 Q4
6 Mar 19
Latest ownership filings
SC 13G/A
AMERIPRISE FINANCIAL INC
14 Feb 22
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 22
SC 13G/A
Park West Asset Management LLC
13 Sep 21
4
Change in insider ownership
13 Sep 21
SC 13D/A
GAMCO INVESTORS, INC. ET AL
31 Aug 21
4
Richard Chin
30 Aug 21
4
Wendy Wee
30 Aug 21
4
Denise Bevers
30 Aug 21
4
Hangjun Zhan
30 Aug 21
4
Ervin Veszpremi
30 Aug 21
Financial summary
| Quarter (USD) | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 46.72 mm | 46.72 mm | 46.72 mm | 46.72 mm | 46.72 mm | 46.72 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 2.85 mm | 3.31 mm | 881.67 k | 2.42 mm |
| Cash used (since last report) | n/a | n/a | 59.92 mm | 69.60 mm | 18.55 mm | 50.90 mm |
| Cash remaining | n/a | n/a | -13.20 mm | -22.89 mm | 28.17 mm | -4.18 mm |
| Runway (months of cash) | n/a | n/a | -4.6 | -6.9 | 31.9 | -1.7 |
Institutional ownership, Q3 2021
5.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 7 |
| Opened positions | 1 |
| Closed positions | 83 |
| Increased positions | 1 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 64.30 mm |
| Total shares | 2.62 mm |
| Total puts | 0.00 |
| Total calls | 109.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Integrated Core Strategies | 2.58 mm | $23.71 mm |
| Mint Tower Capital Management B.V. | 13.93 k | $128.00 k |
| ELAN Elanco Animal Health | 10.00 k | $93.00 k |
| BNP Paribas Arbitrage | 9.41 k | $40.36 mm |
| CVA Family Office | 2.50 k | $11.00 k |
| Gamco Investors | 11.00 | $0.00 |
| Park West Asset Management | 0.00 | $0.00 |
| Parallel Advisors | 0.00 | $0.00 |